Efficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers

Baykara, Meltem; Buyukberber, Suleyman; Ozturk, Banu; Coskun, Ugur; Unsal, Diclehan Kilic; Demirci, Umut; Dane, Faysal; Kaplan, Muhammet Ali; Bora, Huseyin; Benekli, Mustafa

추천

검색

자료유형: 학술저널

저자정보: Baykara, Meltem (Department of Medical Oncology, Sakarya University Training and Research Hospital) Buyukberber, Suleyman (Department of Medical Oncology, Gazi University Medical Faculty) Ozturk, Banu (Gaziosmanpasa University Medical Faculty, Department of Medical Oncology) Coskun, Ugur (Department of Medical Oncology, Gazi University Medical Faculty) Unsal, Diclehan Kilic (Department of Radiation Oncology, Gazi University Medical Faculty) Demirci, Umut (Department of Medical Oncology, Ankara Ataturk Training and Research Hospital) Dane, Faysal (Department of Medical Oncology, Marmara University Medical Faculty) Kaplan, Muhammet Ali (Department of Medical Oncology, Dicle University Medical Faculty) Bora, Huseyin (Department of Radiation Oncology, Gazi University Medical Faculty) Benekli, Mustafa (Department of Medical Oncology, Gazi University Medical Faculty)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제4호

발행연도: 2013.1

수록면: 2,557 - 2,561 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Chemoradiation (CRT) using cisplatin-based regimens has become the standard of care in the treatment of squamous cell head and neck cancers (SCHNC). The impact of taxanes as radiosensitizing agents with concurrent CRT regimens is unknown. We therefore retrospectively evaluated the efficacy and tolerability of a weekly cisplatin+docetaxel combination with CRT in locally advanced SCHNC. Methods: Sixty-six patients with locally advanced SCHNC (39.4% stage IV, 53% stage III, and 7.6% stage II) were assessed retrospectively. Total radiation dose to the PTV of gross disease (primary and/or node) was 70 Gy/35 fractions, 5 fractions per week. Minimum doses of 60 Gy and 50 Gy were administered to PTVs of elective high risk and low risk disease, respectively. Chemotherapy (CT) consisted of weekly cisplatin (20 $mg/m^2$)+docetaxel (20 $mg/m^2$) concurrently with RT. Results: The median age of the patients was 58 years (range, 32-77). Objective response rate was 83.3%. The 2-year progression-free survival (PFS) and overall survival (OS) were 75.7% and 78.3%, respectively. The most common grade 3 and 4 toxicities were mucositis (36.4%), nausea and vomiting (12.1%), neutropenia (4.5%). Conclusion: Weekly cisplatin and docetaxel concurrent with RT for locally advanced SCHNC was found tolerable with high efficacy.

#Squamous cell head and neck cancers #chemoradiotherapy #cisplatin #docetaxel #safety

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요